# 506018222 04/16/2020

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6064935

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

# **CONVEYING PARTY DATA**

Name	Execution Date
SEBASTIAN SCHAEFER	04/17/2018

# **RECEIVING PARTY DATA**

Name:	NATIONAL UNIVERSITY OF SINGAPORE
Street Address:	21 LOWER KENT RIDGE ROAD
City:	SINGAPORE
State/Country:	SINGAPORE
Postal Code:	119077
Name:	SINGAPORE HEALTH SERVICES PTE LTD
Street Address:	31 THIRD HOSPITAL AVENUE #03-03
Internal Address:	BOWYER BLOCK C
City:	SINGAPORE
State/Country:	SINGAPORE
Postal Code:	168753

# **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16726190

### **CORRESPONDENCE DATA**

**Fax Number:** (617)646-8646

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 6176468000

**Email:** Caroline.Kerressey@WolfGreenfield.com,

patents\_JoshuaB@WolfGreenfield.com

Correspondent Name: JOSHUA BRANDT

Address Line 1: WOLF, GREENFIELD & SACKS, P.C.

Address Line 2: 600 ATLANTIC AVENUE

Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	E0601.70002US01
NAME OF SUBMITTER:	JOSHUA M. BRANDT
SIGNATURE:	/Joshua M. Brandt/

PATENT 506018222 REEL: 052418 FRAME: 0818

DATE SIGNED:	04/16/2020			
Total Attachments: 6	·			
source=E060170002US01-ASI-JOB	#page1.tif			
source=E060170002US01-ASI-JOB#page2.tif				
source=E060170002US01-ASI-JOB#page3.tif				
source=E060170002US01-ASI-JOB	#page4.tif			
source=E060170002US01-ASI-JOB#page5.tif				
source=E060170002US01-ASI-JOB	#page6.tif			

#### **ASSIGNMENT OF INVENTIONS & PATENT RIGHTS**

#### **Parties**

- (1) SCHAEFER, SEBASTIAN of 76 Shenton Way, 76 Shenton #24-04, 079119 Singapore, Singapore (the "Inventor");
- (2) NATIONAL HEART CENTRE OF SINGAPORE a company incorporated under the laws of Singapore with CRN/UEN: 199801148C whose registered office is at 31 Third Hospital Avenue, #03-03 Bowyer Block, Singapore 168753 ("NHCS"); and
- (3) NATIONAL UNIVERSITY OF SINGAPORE a company incorporated under the laws of Singapore with CRN/UEN: 200604346E whose registered office is at is at 21 Lower Kent Ridge Road, 119077 Singapore ("NUS");
  - each of NHCS and NUS an "Employer" or together the "Employers" as the context may indicate; and
- (4) SINGAPORE HEALTH SERVICES PTE LTD incorporated and registered in Singapore with CRN/UEN: 200002698Z whose registered office is at 31 Third Hospital Avenue, #03-03, Bowver Block C, 168753 Singapore, Singapore ("SingHealth").

# Background

- A. The Inventor and the Employers believe that, either by operation of law, Intellectual Property Policy or by virtue of an agreement entered into by the Inventor and the Employers before the making of the Invention, the Employers were, at the time the Invention was made, jointly entitled to the whole of the property in the contributions of the Inventor to the Invention.
- B. The Employers are party to the Intellectual Property Agreement dated 28 December 2015 under which the Employers agreed that they are jointly entitled to an equal share in the Invention and the Patent Applications.
- C. NHCS is a wholly-owned subsidiary of SingHealth and under the intra-group governance documents, including the Intellectual Property Policy of the SingHealth healthcare group, NHCS has agreed, at SingHealth's demand, to assign its one half share in the Invention and the Patent Applications to SingHealth on the terms set out in this Assignment.
- D. In order to ensure, and to provide documentary evidence that NUS and SingHealth are the joint owners of the legal and beneficial interest in all the rights, title and interest in, to and arising from the Invention and the Patent Applications, the parties have agreed to execute this Assignment.

1

### Agreed terms

#### 1. Definitions

The definitions in this clause apply in this Assignment.

"Completion Applications" means the completion patent applications, short particulars of which are set out in Part 2 of the Schedule.

"Invention" means the inventions entitled IL-11 ANTIBODIES, IL-11RA ANTIBODIES and DECOY CYTOKINE RECEPTOR being the subject matter of the Priority Applications.

"Patent Applications" means the Priority Applications, the Completion Applications and any future applications linked by one or more priorities to the Priority Applications or the Completion Applications and all matter contained in such applications and any and all:

- (a) national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications;
   and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

"Priority Applications" means the priority patent applications, short particulars of which are set out in Part 1 of the Schedule.

### 2. Assignment

in consideration of the sum of S\$ 1.00 SGD (sufficiency and receipt of which the inventor and the Employers expressly acknowledge), the inventor hereby assigns jointly and absolutely to the Employers and thereafter, NHCS assigns absolutely to SingHealth, its one half share in; all their right, title and interest in all countries, regions and territories of the world in, to and arising from the invention and, with effect from immediately prior to the filing of each, the Patent Applications, including (but not limited to):

- (a) in respect of the invention and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any Patent Application:

Assignment of inventions and PCT/EP2017/083043, PCT/EP2017/083083, PCT/EP2017/083051
RIC/FP/7234841/7234833/7324858 & Fibrosis, IL-11 antibodies, IL-11RA antibodies, Decoy Cytokine
Receptor

- the right to claim priority from and to prosecute and obtain grant of patents; and
- the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country, region or territory in the world, each and any of the Patent Applications and to extend to or register in, or in respect of, any country, region or territory in the world any patent or other intellectual property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any Patent Application; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal proceedings and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Inventions and the Patent Applications, whether occurring before on or after the date of this Assignment.

#### 3. Further assurance

The Inventor and the Employers shall, at the shared cost of NUS and SingHealth, perform all further acts and things, and execute all further documents, required by law or which NUS and SingHealth request to vest in NUS and SingHealth the full benefit of the right, title and interest assigned to NUS and SingHealth under this Assignment, including (but not limited to):

- documents required to be signed by or on behalf of the Inventor or the Employers in the course of any applications which relate to the Invention or to any inventions that shall be disclosed in any of the Patent Applications;
- (b) registration of NUS and SingHealth as joint applicants for, or joint proprietors of, the Patent Applications; and
- (c) assisting NUS and SingHealth in obtaining, defending and enforcing any of the Patent Applications, and assisting with any other proceedings which may be brought by or against the NUS and/or SingHealth by or against any third party or in the resolution of any question concerning the Invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

3

# 4. Right to amend the Schedule

The Inventor, the Employers and SingHealth grant the firm of Mewburn Ellis LLP the right to insert in Part 2 of the Schedule to this Assignment any further identification of any existing or future patent applications in any countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of a patent office for the recordal of this Assignment.

#### 5. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

### 6. Governing law and jurisdiction

This Assignment is governed by the laws of the Republic of Singapore and subject to the exclusive jurisdiction of its courts.

**Schedule: The Patent Applications** 

Part 1: Priority Applications

Country	Application No.	Application Date	Title
GB	1621446.2	16 December 2016	IL-11 ANTIBODIES
GB	1709535.7	15 June 2017	IL-11 ANTIBODIES
GB	1621439.7	16 December 2016	IL-11RA ANTIBODIES
GB	1621431.4	16 December 2016	DECOY CYTOKINE RECEPTOR

Part 2: Completion Applications

Country/region	Application No.	Application Date	Title
WO	PCT/EP2017/083032	15 December 2017	DECOY CYTOKINE RECEPTOR
WO	PCT/EP2017/083043	15 December 2017	IL-11RA ANTIBODIES
WO	PCT/EP2017/083051	15 December 2017	IL-11 ANTIBODIES
US	15/843212	15 December 2017	IL-11RA ANTIBODIES
US	15/843173	15 December 2017	IL-11 ANTIBODIES
TW	106144202	15 December 2017	IL-11RA ANTIBODIES
TW	106144224	15 December 2017	IL-11 ANTIBODIES

4

Assignment of inventions and PCT/EP2017/083043, PCT/EP2017/083083, PCT/EP2017/083051 RIC/FP/7234841/7234833/7324858 & Fibrosis, IL-11 antibodies, IL-11RA antibodies, Decoy Cytokine Receptor

Part 3: Identification of some, but not necessarily all, patent applications failing within the scope of clause 2 of this Assignment

Journal of City today.				
Country/region	Application	Application	Title	Signature for
	No.	Date		Mewburn Ellis LLP

Executed by SEBASTIAN SCHAEFFER in the presence of:	44M	
ALLUC -	signature of inventor  Fry * port  Fry * port	033713
	outaminana CMBA	

Prof 10 **Executed by the NATIONAL HEART** ana∳Smgapor® CENTRE OF SINGAPORE acting by \_\_\_\_\_, an authorised representative, in the presence of: SIGNATURE OF AN ANTHORISED REPRESENTATIVE

SIGNATURE OF WITNESS

NAME:

Scothisone Yare

OCCUPATION Processors Administration & OCCUPATION Processors Administration & DATE: 3- Supposed Heart Centre Singapore

Assignment of inventions and PCT/EP2017/083043, PCT/EP2017/083083, PCT/EP2017/083051
RIC/FP/7234841/7234833/7324858 & Fibrosis, IL-11 antibodies, IL-11RA antibodies, Decoy Cytokine
Receptor

Executed by the NATIONAL

UNIVERSITY OF SINGAPORE acting by fine Thomas (offme) in authorised

representative, in the presence of:

SIGNATURE OF WITNESS

NAME:

Cynthia Chew

ADDRESS:

OCCUPATION: EXECUTIVE, DAFE-NUS

DATE: 7 Jun 2018

medical school

money de anno

SIGNATURE OF AN AUTHORISED

N AUTHORISED

Thomas M. COFFMAN M.D.

Duke-NUS Medical School

REPRESENTATIVE

REPRESENTATIVE

Executed by SINGAPORE HEALTH

SERVICES PTE LTD acting by

an authorised

representative, in the presence of:

SIGNATURE OF WITNESS

NAME:

Koh Choon Heng Assistant Director

Assistant Dire

ADDRESS:

SingHealth Intellectual Property (SHIP) Singapore Health Services Pie Uni

OCCUPATION:

DATE: May 24, 2018